128TiP A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)

医学 贝伐单抗 结直肠癌 内科学 临床研究阶段 肿瘤科 癌症研究 癌症 化疗
作者
Ren Lin,Sihai Zhao,Liang Su,Yong Sang Hong,Jie Luo,Y. Wei,Sihai Dave Zhao
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1519-S1519
标识
DOI:10.1016/j.annonc.2023.10.263
摘要

Immune-checkpoint inhibitors (ICI) show modest activity and efficacy in patients with MSS mCRC and pMMR. A recent trial of botensilimab (next-generation anti–CTLA-4 antibody) + balstilimab (anti-PD-1 antibody) for heavily pretreated pMMR/MSS mCRC reported promising results. Cadonilimab is a humanized bi-specific antibody that targets both PD-1 and CTLA-4. Its higher binding avidity in a tumor-like setting and Fc-null design may increase drug retention in tumors and improve safety. A more intensive chemotherapy, FOLFOXIRI + bevacizumab, can enhance the antitumor effect of ICI by increasing tumor immunogenicity. AtezoTRIBE, a phase II study, showed that adding atezolizumab to first-line FOLFOXIRI + bevacizumab might improve progression-free survival (PFS) in patients with mCRC. Therefore, in this study we aim to investigate the efficacy and safety of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for patients with unresectable pMMR/MSS mCRC. This is a multicenter single arm phase II study. Eligibility criteria include: histologically or cytologically confirmed pMMR/MSS mCRC; age 18-75 years; naive to systemic treatment in the metastatic setting; at least 1 measurable lesion according to RECIST 1.1; ECOG PS 0-1; and adequate organ function. Patients with high microsatellite instability (MSI-H) tumors and those who previously received immunotherapy are excluded. Twenty eligible participants will receive FOLFOXIRI (intravenous [i.v.] irinotecan 165 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2400 mg/m2 as a 48-h infusion) + bevacizumab 5 mg/kg i.v. and cadonilimab 6 mg/kg i.v. Treatment is administered for up to twelve 14-day cycles followed by maintenance with fluorouracil and leucovorin (or capecitabine) + bevacizumab and cadonilimab for a total of 52 weeks or until disease progression, unacceptable adverse events, or consent withdrawal. The primary endpoint is objective response rate per RECIST 1.1. Secondary endpoints are PFS, overall survival, and safety. Enrollment is ongoing. NCT05839470. The authors. Akeso, Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
唐唐完成签到 ,获得积分10
4秒前
最棒哒完成签到 ,获得积分10
4秒前
鸣鸣完成签到,获得积分10
5秒前
123321完成签到 ,获得积分10
6秒前
卓若之完成签到 ,获得积分10
7秒前
苯二氮卓完成签到,获得积分10
8秒前
温暖完成签到 ,获得积分10
10秒前
mojomars完成签到,获得积分10
10秒前
时尚雨兰完成签到,获得积分0
11秒前
一叶知秋完成签到,获得积分10
13秒前
叶123完成签到,获得积分10
14秒前
量子星尘发布了新的文献求助10
15秒前
Minicoper发布了新的文献求助10
15秒前
背书强完成签到 ,获得积分10
16秒前
淡然以柳完成签到 ,获得积分10
18秒前
dolabmu完成签到 ,获得积分10
21秒前
崔崔完成签到 ,获得积分10
25秒前
SYLH应助xcxc采纳,获得10
26秒前
wp4455777完成签到,获得积分10
27秒前
十一完成签到,获得积分10
27秒前
ru完成签到 ,获得积分10
29秒前
慧木完成签到 ,获得积分10
29秒前
WW完成签到 ,获得积分10
30秒前
小高同学完成签到,获得积分10
31秒前
轻轻1完成签到,获得积分10
34秒前
35秒前
大橙子发布了新的文献求助10
39秒前
iuhgnor完成签到,获得积分10
42秒前
可夫司机完成签到 ,获得积分10
45秒前
yang完成签到,获得积分10
47秒前
一1完成签到 ,获得积分10
49秒前
jiaolulu完成签到,获得积分10
49秒前
量子星尘发布了新的文献求助10
51秒前
爆米花应助LiZhao采纳,获得10
51秒前
轻轻完成签到,获得积分10
54秒前
Orange应助jiaolulu采纳,获得10
54秒前
xcxc完成签到,获得积分10
56秒前
water应助科研通管家采纳,获得50
56秒前
56秒前
默存完成签到,获得积分10
59秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022